NVIDIA and Eli Lilly announced a five‑year, $1 billion co‑innovation AI lab to accelerate computing and AI applications in drug discovery and development. The agreement brings NVIDIA’s accelerated computing and AI stack together with Lilly’s drug‑discovery capabilities to build scalable AI models, large‑scale datasets and co‑designed infrastructure for pharma use cases. Executives framed the pact as a strategic push to scale generative and mechanistic AI across target identification, molecular design and translational modeling. The collaboration includes joint engineering, shared datasets and investments in compute capacity and is being marketed as a template for deep industry‑tech partnerships that aim to shorten discovery timelines.